Jared Barsky
Examiner (ID: 13656, Phone: (571)272-2795 , Office: P/1628 )
Most Active Art Unit | 1628 |
Art Unit(s) | 1628 |
Total Applications | 964 |
Issued Applications | 443 |
Pending Applications | 93 |
Abandoned Applications | 428 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 16086941
[patent_doc_number] => 20200197457
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => ONCOLYTIC VIRUS FOR EXPRESSION OF IMMUNE CHECKPOINT MODULATORS
[patent_app_type] => utility
[patent_app_number] => 16/725485
[patent_app_country] => US
[patent_app_date] => 2019-12-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17620
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16725485
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/725485 | Oncolytic virus for expression of immune checkpoint modulators | Dec 22, 2019 | Issued |
Array
(
[id] => 15931079
[patent_doc_number] => 20200157173
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-21
[patent_title] => CHIMERIC ANTIGEN RECEPTOR, REGULATORY CELLS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 16/715077
[patent_app_country] => US
[patent_app_date] => 2019-12-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10300
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16715077
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/715077 | CHIMERIC ANTIGEN RECEPTOR, REGULATORY CELLS AND METHODS OF USE | Dec 15, 2019 | Abandoned |
Array
(
[id] => 15676885
[patent_doc_number] => 20200093106
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-26
[patent_title] => HUMANIZED NON-HUMAN ANIMALS WITH RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN LOCI
[patent_app_type] => utility
[patent_app_number] => 16/703116
[patent_app_country] => US
[patent_app_date] => 2019-12-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49536
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16703116
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/703116 | Humanized non-human animals with restricted immunoglobulin heavy chain loci | Dec 3, 2019 | Issued |
Array
(
[id] => 15590331
[patent_doc_number] => 20200071700
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-05
[patent_title] => COMPOSITION AND METHOD OF USING MIR-302 PRECURSORS AS DRUGS FOR TREATING ALZHEIMER'S DISEASES
[patent_app_type] => utility
[patent_app_number] => 16/687501
[patent_app_country] => US
[patent_app_date] => 2019-11-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15715
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 71
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16687501
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/687501 | COMPOSITION AND METHOD OF USING MIR-302 PRECURSORS AS DRUGS FOR TREATING ALZHEIMER'S DISEASES | Nov 17, 2019 | Abandoned |
Array
(
[id] => 17937067
[patent_doc_number] => 11471499
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-10-18
[patent_title] => Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
[patent_app_type] => utility
[patent_app_number] => 16/684241
[patent_app_country] => US
[patent_app_date] => 2019-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 41
[patent_no_of_words] => 23208
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16684241
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/684241 | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia | Nov 13, 2019 | Issued |
Array
(
[id] => 17385929
[patent_doc_number] => 20220033781
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => ARTIFICIAL RECOMBINANT CHROMOSOME AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/626816
[patent_app_country] => US
[patent_app_date] => 2019-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 50507
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16626816
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/626816 | ARTIFICIAL RECOMBINANT CHROMOSOME AND USE THEREOF | Nov 11, 2019 | Pending |
Array
(
[id] => 17292235
[patent_doc_number] => 20210388074
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => HUMANIZED AND VARIANT TGF-BETA3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/290834
[patent_app_country] => US
[patent_app_date] => 2019-11-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36480
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290834
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/290834 | HUMANIZED AND VARIANT TGF-BETA3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF | Nov 3, 2019 | Pending |
Array
(
[id] => 17292277
[patent_doc_number] => 20210388116
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => COMPOSITIONS AND METHODS FOR DIAGNOSIS OF CARDIOVASCULAR DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/290843
[patent_app_country] => US
[patent_app_date] => 2019-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23980
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290843
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/290843 | COMPOSITIONS AND METHODS FOR DIAGNOSIS OF CARDIOVASCULAR DISEASE | Oct 31, 2019 | Pending |
Array
(
[id] => 15553419
[patent_doc_number] => 20200061121
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-02-27
[patent_title] => Non-invasive in vivo imaging and methods for treating type I diabetes
[patent_app_type] => utility
[patent_app_number] => 16/669840
[patent_app_country] => US
[patent_app_date] => 2019-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11324
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16669840
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/669840 | Non-invasive in vivo imaging and methods for treating type I diabetes | Oct 30, 2019 | Abandoned |
Array
(
[id] => 15963753
[patent_doc_number] => 20200165628
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-28
[patent_title] => TISSUE SELECTIVE TRANSGENE EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 16/670996
[patent_app_country] => US
[patent_app_date] => 2019-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36195
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16670996
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/670996 | TISSUE SELECTIVE TRANSGENE EXPRESSION | Oct 30, 2019 | Abandoned |
Array
(
[id] => 16619988
[patent_doc_number] => 20210038641
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-11
[patent_title] => Method for Producing an Exosome Containing Agent for Metastasis Suppression
[patent_app_type] => utility
[patent_app_number] => 16/668581
[patent_app_country] => US
[patent_app_date] => 2019-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2587
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 122
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16668581
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/668581 | Method for Producing an Exosome Containing Agent for Metastasis Suppression | Oct 29, 2019 | Abandoned |
Array
(
[id] => 16619988
[patent_doc_number] => 20210038641
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-11
[patent_title] => Method for Producing an Exosome Containing Agent for Metastasis Suppression
[patent_app_type] => utility
[patent_app_number] => 16/668581
[patent_app_country] => US
[patent_app_date] => 2019-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 2587
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 122
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16668581
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/668581 | Method for Producing an Exosome Containing Agent for Metastasis Suppression | Oct 29, 2019 | Abandoned |
Array
(
[id] => 16310890
[patent_doc_number] => 20200289628
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => COMPOSITIONS AND METHODS FOR EXPRESSING FACTOR IX
[patent_app_type] => utility
[patent_app_number] => 16/657961
[patent_app_country] => US
[patent_app_date] => 2019-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47677
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16657961
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/657961 | COMPOSITIONS AND METHODS FOR EXPRESSING FACTOR IX | Oct 17, 2019 | Pending |
Array
(
[id] => 15765937
[patent_doc_number] => 20200113986
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-04-16
[patent_title] => GENOME EDITED CANCER CELL VACCINES
[patent_app_type] => utility
[patent_app_number] => 16/596829
[patent_app_country] => US
[patent_app_date] => 2019-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30067
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 27
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16596829
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/596829 | GENOME EDITED CANCER CELL VACCINES | Oct 8, 2019 | Pending |
Array
(
[id] => 15676883
[patent_doc_number] => 20200093105
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-03-26
[patent_title] => Genetically Modified Non-Human Animals And Methods Of Use Thereof
[patent_app_type] => utility
[patent_app_number] => 16/586573
[patent_app_country] => US
[patent_app_date] => 2019-09-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17804
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16586573
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/586573 | Genetically modified non-human animals and methods of use thereof | Sep 26, 2019 | Issued |
Array
(
[id] => 17399623
[patent_doc_number] => 20220041713
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => TARGETED IMMUNOTOLERANCE
[patent_app_type] => utility
[patent_app_number] => 17/277008
[patent_app_country] => US
[patent_app_date] => 2019-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51051
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17277008
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/277008 | TARGETED IMMUNOTOLERANCE | Sep 17, 2019 | Pending |
Array
(
[id] => 16203925
[patent_doc_number] => 20200236915
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => HUMAN ARTIFICIAL CHROMOSOME CONTAINING HUMAN ANTIBODY LAMBDA LIGHT CHAIN GENE AND NON-HUMAN ANIMAL CONTAINING THE HUMAN ARTIFICIAL CHROMOSOME CAPABLE OF GENETIC TRANSMISSION
[patent_app_type] => utility
[patent_app_number] => 16/568616
[patent_app_country] => US
[patent_app_date] => 2019-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14581
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16568616
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/568616 | HUMAN ARTIFICIAL CHROMOSOME CONTAINING HUMAN ANTIBODY LAMBDA LIGHT CHAIN GENE AND NON-HUMAN ANIMAL CONTAINING THE HUMAN ARTIFICIAL CHROMOSOME CAPABLE OF GENETIC TRANSMISSION | Sep 11, 2019 | Abandoned |
Array
(
[id] => 16549971
[patent_doc_number] => 10883120
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-01-05
[patent_title] => DNA plasmids for the fast generation of homologous recombination vectors for cell line development
[patent_app_type] => utility
[patent_app_number] => 16/568771
[patent_app_country] => US
[patent_app_date] => 2019-09-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 12
[patent_no_of_words] => 15865
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16568771
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/568771 | DNA plasmids for the fast generation of homologous recombination vectors for cell line development | Sep 11, 2019 | Issued |
Array
(
[id] => 15324121
[patent_doc_number] => 20200002390
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-01-02
[patent_title] => HTT REPRESSORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/550949
[patent_app_country] => US
[patent_app_date] => 2019-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25494
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16550949
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/550949 | Htt repressors and uses thereof | Aug 25, 2019 | Issued |
Array
(
[id] => 17460293
[patent_doc_number] => 20220073598
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => ANTAGONISTS
[patent_app_type] => utility
[patent_app_number] => 17/279513
[patent_app_country] => US
[patent_app_date] => 2019-08-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 71582
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279513
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/279513 | ANTAGONISTS | Aug 14, 2019 | Pending |